Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Multiple Endocrine Neoplasia Type 2a 1Lung Neoplasms 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Liquid Biopsy × Endocrine × Clear all
NCT05255133 2025-01-06

Liquid-NET

Universiteit Antwerpen

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05268952 2022-03-07

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

University Hospital, Antwerp

Phase NA Unknown
100 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡